Q2 EBITDA jumps 84.6%; FY27 revenue and margin guidance raised
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 revenue rose 42.7% to ₹4,369 million, led by drug intermediates. EBITDA rose 84.6% to ₹1,760 million and margin improved to 40.3% from 31.1%; PAT rose 71.4% to ₹1,231 million. H1 revenue was ₹7,666 million, up 49.3%. Management cited a robust order pipeline, raised FY27 revenue growth guidance to around 30% from 25%, and lifted EBITDA margin guidance to 38-40%. South Korea semiconductor plant opened early; specialty chemicals stayed soft.
Strong profit growth, higher guidance and semiconductor capacity support optimism, though specialty chemicals weakness and execution risks remain.